| Company/Division name | Artiva Biotherapeutics Inc |
| Parent company | GC Labcell |
| Type of work | Manufacturing |
| If manufacturing, is the company an OEM? | Yes |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2022 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | Korea, Republic of |
| City reshored to: | San Diego |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | off-the-shelf NK, CAR-NK therapeutics, AB-201 |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Infrastructure, Skilled workforce availability/training |
